Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EV68-228-N, a human monoclonal IgG1 against the capsid of enterovirus D68 (EV-D68) designed as an intravenous therapeutic for the treatment of acute flaccid myelitis (AFM).
Lead Product(s): EV68-228-N
Therapeutic Area: Rare Diseases and Disorders Product Name: EV68-228-N
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Details:
The collaboration will support the activities as development of new technologies to improve ongoing research activities, enhance expression and production of proteins within plants and for development of new approaches and plant lines to increase plant-derived product yields.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leaf Expression Systems
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 28, 2022
Details:
Under the terms of the agreement, KBio will have development rights to select assets within ZabBio’s current pipeline of antibody therapies – including a late-stage preclinical anti-fungal mAb – as well as future products discovered under the collaboration.
Lead Product(s): Monoclonal Antibody-based Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ZabBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 13, 2022